JPMorgan Chase & Co. Has $5.95 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)

JPMorgan Chase & Co. decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 93.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,834 shares of the biotechnology company’s stock after selling 577,428 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.07% of Ascendis Pharma A/S worth $5,948,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at $30,000. Groupama Asset Managment bought a new stake in Ascendis Pharma A/S during the 3rd quarter worth about $60,000. Signaturefd LLC increased its position in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 143 shares during the last quarter. Finally, Pursue Wealth Partners LLC acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth approximately $217,000.

Ascendis Pharma A/S Stock Performance

ASND opened at $131.62 on Friday. The firm’s fifty day moving average is $132.95 and its two-hundred day moving average is $133.55. The firm has a market cap of $7.99 billion, a PE ratio of -16.29 and a beta of 0.65. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00.

Analysts Set New Price Targets

Several research firms have recently commented on ASND. Oppenheimer decreased their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. JPMorgan Chase & Co. dropped their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Bank of America upped their price target on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, TD Cowen lowered their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of “Moderate Buy” and an average price target of $192.07.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.